- Home
- CGNT vs OMER Comparison
CGNT vs OMER Comparison
Compare CGNT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- OMER
- Stock Information
- Founded
- CGNT 2020
- OMER 1994
- Country
- CGNT Israel
- OMER United States
- Employees
- CGNT N/A
- OMER N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- OMER Health Care
- Exchange
- CGNT Nasdaq
- OMER Nasdaq
- Market Cap
- CGNT 639.4M
- OMER 579.5M
- IPO Year
- CGNT N/A
- OMER 2009
- Fundamental
- Price
- CGNT $9.78
- OMER $9.18
- Analyst Decision
- CGNT Hold
- OMER Buy
- Analyst Count
- CGNT 3
- OMER 4
- Target Price
- CGNT $8.25
- OMER $22.50
- AVG Volume (30 Days)
- CGNT 263.8K
- OMER 1.1M
- Earning Date
- CGNT 12-11-2024
- OMER 11-13-2024
- Dividend Yield
- CGNT N/A
- OMER N/A
- EPS Growth
- CGNT N/A
- OMER N/A
- EPS
- CGNT N/A
- OMER N/A
- Revenue
- CGNT $339,818,000.00
- OMER N/A
- Revenue This Year
- CGNT $13.67
- OMER N/A
- Revenue Next Year
- CGNT $6.92
- OMER N/A
- P/E Ratio
- CGNT N/A
- OMER N/A
- Revenue Growth
- CGNT 12.16
- OMER N/A
- 52 Week Low
- CGNT $5.68
- OMER $2.61
- 52 Week High
- CGNT $9.97
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- CGNT 69.72
- OMER 48.50
- Support Level
- CGNT $8.47
- OMER $8.21
- Resistance Level
- CGNT $9.05
- OMER $11.26
- Average True Range (ATR)
- CGNT 0.30
- OMER 0.92
- MACD
- CGNT 0.04
- OMER -0.24
- Stochastic Oscillator
- CGNT 87.33
- OMER 27.17
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.